Abstracts tagged "Biologics"

Abstract Number: 3194 • 2016 ACR/ARHP Annual Meeting
Factors Related to Physicians’ Prescriptions for Rheumatoid Arthritis Drugs Never Filled or Subsequently Discontinued By Patients
Hong J. Kan¹, Kirill Dyagilev¹, Peter Schulam², Suchi Saria¹, Charles Molta³ and Jeffrey Curtis⁴, ¹John Hopkins University, Baltimore, MD, ²Department of Computer Science, Johns Hopkins University, Baltimore, MD, ³Sun Pharmaceutical, Cranbury, NJ, ⁴Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Rheumatologists have many choices of medications to use for patients with rheumatoid arthritis (RA), but patients may not fill a prescription (primary non-adherence or…
Abstract Number: 433 • 2016 ACR/ARHP Annual Meeting
The Prevalence of Latent Tuberculosis and Hepatitis B Found after Systematic Screening of Patients Starting with Biological Therapy in a Low-Endemic Area
Marin de Jong^1,2, Danielle Roosen¹, Andy Peters¹, Valerie Verstraeten³, Marieke Pierik¹ and A. van Tubergen⁴, ¹Department of Internal Medicine, division of Gastroenterology, Maastricht University Medical Centre, Maastricht, Netherlands, ²NUTRIM – School for Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre, Maastricht, Netherlands, ³Department of Dermatology, Maastricht University Medical Centre, Maastricht, Netherlands, ⁴Department of Internal Medicine, Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: Biologicals are a powerful treatment option for moderate to severe immune-mediated inflammatory diseases (IMID). Since biologicals modulate the immune system, the risk for reactivation…
Abstract Number: 1625 • 2016 ACR/ARHP Annual Meeting
Analysis of a Phase 3 Study Evaluating the Efficacy of Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, Across Subgroups in Patients with Active Rheumatoid Arthritis Despite Treatment with Disease-Modifying Anti-Rheumatic Drugs
Carter Thorne¹, George Karpouzas², Tsutomu Takeuchi³, Shihong Sheng⁴, Weichun Xu⁴, Ravi Rao⁵, Kaiyin Fei⁴ and Benjamin Hsu⁴, ¹University of Toronto and Southlake Regional Health Centre, Newmarket, ON, Canada, ²Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ³Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom
Background/Purpose: Sirukumab is a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, and is under development for rheumatoid arthritis (RA)…
Abstract Number: 2172 • 2016 ACR/ARHP Annual Meeting
Impact of Biologic and Non-Biologic Treatment on the Incidence of Traditional Cardiovascular Risk Factors Among Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis
Helga Radner¹, Tamara Lesperance², Neil A. Accortt³ and Daniel H. Solomon⁴, ¹Rheumatology, Medical University of Vienna, Vienna, Austria, ²DOCS Global, Inc., North Wales, PA, ³Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Studies have suggested that the chronic inflammatory nature of rheumatic conditions (rheumatoid arthritis (RA) and psoriatic arthritis (PsA)) as well as psoriasis (PsO) may…
Abstract Number: 3224 • 2016 ACR/ARHP Annual Meeting
Efficacy of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, Based upon Prior Use of Non-Anti-TNF Biologics in Patients with Active Rheumatoid Arthritis Despite Anti-TNF Therapy: Results from a Global Phase 3 Study
Yoshiya Tanaka¹, Daniel Aletaha², Clifton Bingham III³, Prasheen Agarwal⁴, Regina Kurrasch⁵ and Sharon Popik⁴, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵GlaxoSmithKline, King of Prussia, PA
Background/Purpose: A global, phase 3 study (SIRROUND-T) evaluating the efficacy and safety of sirukumab, a selective, high-affinity human monoclonal antibody to IL-6, has recently been…
Abstract Number: 600 • 2016 ACR/ARHP Annual Meeting
Disease Activity Trends after Dose Escalation of Infliximab (Remicade) – Results from United States Consortium of Rheumatology Researchers of North America Registry
Dennis Parenti¹, George W. Reed², Ying Shan², Kimberly Dandreo², Joel M. Kremer³ and Raphael J. DeHoratius⁴, ¹Janssen Scientific Affairs, LLC, Horsham, PA, ²Corrona, LLC, Southborough, MA, ³Albany Medical College, Albany, NY, ⁴Janssen Scientific Affairs, LLC/Sidney Kimmel School of Medicine, Thomas Jefferson University, Horsham/Philadelphia, PA
Background/Purpose: Dose escalation is a common strategy for patients (pts) on infliximab (IFX). This study examined the trend in disease activity across dose escalations to…
Abstract Number: 1627 • 2016 ACR/ARHP Annual Meeting
Network Meta-Analysis to Assess the Relative Efficacy of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Combination Therapy for Patients with Active Rheumatoid Arthritis Despite Conventional Dmards
Steve Peterson¹, Maud Pacou², Drifa Belhadi², Suzy Van Sanden¹, Thomas Webb¹, Rita Ganguly³, Regina Kurrasch³, Ravi Rao³, Benjamin Hsu¹, Kaiyin Fei¹, Danuta Kielar¹ and Rafael Alfonso³, ¹Janssen Research & Development, LLC, Spring House, PA, ²Amaris, Paris, France, ³GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom
Background/Purpose: Sirukumab is a human anti-interleukin-6 cytokine monoclonal antibody evaluated for the treatment of moderate to severe active rheumatoid arthritis (RA) and other diseases. Our…
Abstract Number: 2548 • 2016 ACR/ARHP Annual Meeting
Single 1g Infusion Vs Double 1g Infusion of Rituximab in Rheumatoid Arthritis in a Large Teaching Hospital: Potential Clinical Benefits and Financial Savings
Ben Roberts¹, Alexander Langridge², John Wilkinson³, Elliot Jones⁴, Edward Lea², Ben Hargreaves⁵, David Walker⁶ and Martin Lee³, ¹Rheumatology, Newcastle University, Newcastle, United Kingdom, ²Rheumatology, Freeman Hospital, Newcastle, United Kingdom, ³Freeman Hospital, Newcastle, United Kingdom, ⁴Newcastle University, Newcastle, United Kingdom, ⁵Musculoskeletal Directorate, Newcastle upon Tyne NHS Foundation Trust, Newcastle, United Kingdom, ⁶Rake Lane, Northumbria Healthcare, Newcastle Upon Tyne, United Kingdom
Background/Purpose: Recent trial data from Mariette et al. investigating a single-dose 1g rituximab regimen as opposed to a double-dose 1g rituximab regimen in patients with…
Abstract Number: 3225 • 2016 ACR/ARHP Annual Meeting
Dual Cytokine Inhibition with ABT-122, a Tnf– and IL-17–Targeted Dual Variable Domain Immunoglobulin (DVD-Ig™): Results from a 24-Week Open-Label Extension Study in Patients with Rheumatoid Arthritis
Mark C. Genovese¹, Michael Weinblatt², Heikki T. Mansikka³, Paul M. Peloso³, Kun Chen³, Yihan Li³, John Liu³ and Robert J. Padley³, ¹Stanford University Medical Center, Palo Alto, CA, ²Brigham and Women’s Hospital, Boston, MA, ³AbbVie Inc., North Chicago, IL
Background/Purpose: ABT-122 is a dual variable domain immunoglobulin (DVD-Ig™) that targets human tumor necrosis factor-α (TNF-α) and interleukin-17A (IL-17A). The object was to investigate the…
Abstract Number: 13L • 2015 ACR/ARHP Annual Meeting
Safety and Efficacy of E6011, an Anti-Fractalkine Monoclonal Antibody, in a First-in-Patient Phase 1/2 Study in Rheumatoid Arthritis
Yoshiya Tanaka¹, Tsutomu Takeuchi², Hisanori Umehara³, Toshihiro Nanki⁴, Hideto Akama⁵, Nobuyuki Yasuda⁵, Fumitoshi Tago⁵, Makoto Kawakubo⁵, Seiichiro Hojo⁵, Tetsu Kawano⁶ and Toshio Imai⁶, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Dept. of Internal Medicine, School of Medicine Keio University, Tokyo, Japan, ³Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁴School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan, ⁵EISAI Co. Ltd., Tokyo, Japan, ⁶KAN Research Institute, Inc., Kobe, Japan
Background/Purpose: Fractalkine (CX3CL1, designated as FKN hereafter) is the sole member of the CX3C-chemokine which leads to dual actions, chemotaxis and cell adhesion for leukocytes…
Abstract Number: 550 • 2015 ACR/ARHP Annual Meeting
Can Anti-TNF-Induced Autoantibody Conversion be Reversed By Switching to Abatacept Therapy in Patients with RA on Background MTX?
Maya H. Buch¹, A Johnsen², DA Wong² and M Schiff³, ¹University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ²Bristol-Myers Squibb, Princeton, NJ, ³University of Colorado, Denver, CO
Background/Purpose: Anti-TNF therapy for RA is associated with antinuclear (ANAs) and anti-double-stranded DNA (anti-dsDNA) autoantibodies.1,2 The effect of biologics on autoantibody-positive patients is unknown. We…
Abstract Number: 1658 • 2015 ACR/ARHP Annual Meeting
Rheumatoid Factor Status Affects the Efficacy of First Biological Treatment in RA
Yoshikazu Ogawa¹, Nobunori Takahashi², Koji Funahashi², Shuji Asai³, Toki Takemoto³, Tatsuo Watanabe³, Nobuyuki Asai², Naoki Ishiguro⁴ and Toshihisa Kojima², ¹orthopedic surgery, Nagoya University Hospital, Nagoya, Japan, ²Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ³Nagoya University Hospital, Nagoya, Japan, ⁴Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: Rheumatoid factor (RF) is considered an important factor in diagnosing rheumatoid arthritis (RA). The association between the treatment efficacy of biological agents and RF…
Abstract Number: 2769 • 2015 ACR/ARHP Annual Meeting
Factors Associated with TNF Switching: a Retrospective Real-World Study of Patients with Rheumatoid Arthritis
Wenhui Wei¹, Keith Knapp², Li Wang³, Chieh-I Chen⁴, Gary Craig², Karen Ferguson² and Sergio Schwartzman⁵, ¹Sanofi-Aventis, Bridgewater, NJ, ²Discus Analytics, Inc., Spokane, WA, ³Director, Analytic Research, STATinMED Research, Plano, TX, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Hospital for Special Surgery, New York, NY
Background/Purpose: Switching of disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patient treatment is common in real-world clinical practice. The context for why patients switch…
Abstract Number: 565 • 2015 ACR/ARHP Annual Meeting
Factors Associated with Sustained Response in Patients with Rheumatoid Arthritis Who Received Rituximab within the US Corrona Registry
Leslie Harrold^1,2, Ani John³, George W. Reed¹, Chitra Karki², Robert Magner¹, Joel M. Kremer⁴, Ashwini Shewede³ and Jeffrey Greenberg^2,5, ¹University of Massachusetts Medical School, Worcester, MA, ²Corrona, LLC, Southborough, MA, ³Genentech, Inc., South San Francisco, CA, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY, ⁵NYU School of Medicine, New York, NY
Background/Purpose: The goal of treatment for patients with rheumatoid arthritis (RA) is to achieve and maintain low disease activity (LDA) or remission. Little information is…
Abstract Number: 1672 • 2015 ACR/ARHP Annual Meeting
One-Year Safety of Sirukumab Monotherapy: Results from a Randomized, Double-Blind, Parallel-Group, Multicenter Study in Japanese Subjects with Moderate to Severe Rheumatoid Arthritis
Tsutomu Takeuchi¹, Hisashi Yamanaka², Masayoshi Harigai³, Ryo Tamamura⁴, Yuchi Kato⁴, Yoshifumi Ukyo⁴, Toshikazu Nakano⁴, Takayuki Ota⁴, Benjamin Hsu⁵ and Yoshiya Tanaka⁶, ¹Keio University School of Medicine, Tokyo, Japan, ²Dept. of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ³Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, ⁴Janssen Pharmaceutical K.K., Tokyo, Japan, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶The First Dept. of Internal Medicine, University of Occupational & Environmental Health, Kitakyusyu, Japan
Background/Purpose: Interleukin-6 (IL-6) is a pleiotropic cytokine known for its proinflammatory functions. In rheumatoid arthritis (RA), increased concentrations of IL-6 may stimulate leukocyte recruitment to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.